Adenocarcinoma of unknown primary

From HemOnc.org - A Hematology Oncology Wiki
(Redirected from Unknown primary)
Jump to: navigation, search

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Adenocarcinoma of unknown primary may also be referred to as carcinoma of unknown primary site, cancer/carcinoma of unknown primary (CUP), occult primary, or unknown primary carcinoma.

12 regimens on this page
13 variants on this page


Guidelines

ESMO

NCCN

All lines of therapy

Bleomycin, Cisplatin, Etoposide

back to top

Regimen

Study Evidence
Hainsworth et al 1992 Phase II

Chemotherapy

21-day cycles

References

  1. Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992 Jun;10(6):912-22. link to original article contains verified protocol PubMed

Carboplatin & Docetaxel

back to top

Regimen #1

Study Evidence
Pentheroudakis et al. 2008 Phase II

Chemotherapy

Supportive medications

21-day cycle for up to 8 cycles

Regimen #2

Study Evidence
Greco et al. 2000 Phase II

Chemotherapy

Supportive medications

21-day cycle for 4 to 8 cycles

References

  1. Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000 Feb;11(2):211 to 5. link to original article contains verified protocol PubMed
  2. Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N; Hellenic Cooperative Oncology Group. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol. 2008;47(6):1148-55. link to original article contains verified protocol PubMed

Carboplatin, Gemcitabine, Paclitaxel

back to top

Regimen

Study Evidence
Greco et al. 2002 Phase II

Chemotherapy

Supportive medications

21-day cycles

References

  1. Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002 Mar 15;20(6):1651-6. link to original article contains verified protocol PubMed

Carboplatin & Paclitaxel

back to top

Regimen

Study Evidence
Briasoulis et al. 2000 Phase II

Chemotherapy

Supportive medications

21-day cycle for 6 to 8 cycles

References

  1. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000 Sep;18(17):3101-7. link to original article contains verified protocol PubMed

Cisplatin monotherapy

back to top

Regimen

Study Evidence Comparator Efficacy
Gross-Goupil et al. 2012 (GEFCAPI 02) Randomized Phase II Cisplatin & Gemcitabine Seems not superior

Chemotherapy

21-day cycles

References

  1. Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012 Mar;48(5):721-7. Epub 2012 Feb 6. link to original article contains verified protocol PubMed

Cisplatin & Docetaxel

back to top

Regimen

Study Evidence
Greco et al. 2000 Phase II

Chemotherapy

Supportive medications

21-day cycle for up to 8 cycles

References

  1. Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000 Feb;11(2):211 to 5. link to original article contains verified protocol PubMed

Cisplatin & Gemcitabine

back to top

Regimen

Study Evidence Comparator Efficacy
Culine et al. 2003 (GEFCAPI 01) Randomized Phase II Cisplatin & Irinotecan Not reported
Gross-Goupil et al. 2012 (GEFCAPI 02) Randomized Phase II Cisplatin Seems not superior

Chemotherapy

21-day cycles

References

  1. Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003 Sep 15;21(18):3479-82. link to original article contains verified protocol PubMed content property of HemOnc.org
  2. Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012 Mar;48(5):721-7. Epub 2012 Feb 6. link to original article contains verified protocol PubMed

Cisplatin & Irinotecan

back to top

Regimen

Study Evidence Comparator Efficacy
Culine et al. 2003 (GEFCAPI 01) Randomized Phase II Cisplatin & Gemcitabine Not reported

Chemotherapy

21-day cycles

References

  1. Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003 Sep 15;21(18):3479-82. link to original article contains verified protocol PubMed

Docetaxel & Gemcitabine

back to top

Regimen

Study Evidence
Pouessel et al. 2004 Phase II

Chemotherapy

Supportive medications

21-day cycle for up to 6 cycles

References

  1. Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, Cupissol D, Pinguet F. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer. 2004 Mar 15;100(6):1257-61. link to original article contains verified protocol PubMed

Erlotinib & Bevacizumab

back to top

Regimen

Study Evidence
Hainsworth et al. 2007 Phase II

Chemotherapy

  • Erlotinib (Tarceva) 150 mg PO on days 1 to 28, 1 hour before or 2 hours after meals
  • Bevacizumab (Avastin) 10 mg/kg IV once per day on days 1 & 15
    • Infusion time is 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later

28-day cycles

References

  1. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA; Minnie Pearl Cancer Research Network. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007 May 1;25(13):1747-52. link to original article contains verified protocol PubMed

Gemcitabine & Irinotecan

back to top

Regimen

Study Evidence Comparator Efficacy
Hainsworth et al. 2010 Phase III PCE Seems not superior

Chemotherapy

21-day cycle for up to 6 cycles

References

  1. Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM, Cescon T, Bury MJ, Greco FA. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010 Jan-Feb;16(1):70-5. link to original article PubMed

PCE

back to top

PCE: Paclitaxel, Carboplatin, Etoposide

Regimen

Study Evidence Comparator Efficacy
Greco et al. 2000 Phase II
Hainsworth et al. 2010 Phase III Gemcitabine & Irinotecan Seems not superior

Chemotherapy

Supportive medications

21-day cycle for 4 to 8 cycles

References

  1. Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD. Carcinoma of unknown primary site. Cancer. 2000 Dec 15;89(12):2655-60. link to original article contains verified protocol PubMed
  2. Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM, Cescon T, Bury MJ, Greco FA. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010 Jan-Feb;16(1):70-5. link to original article PubMed